Patents
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/2003
06/26/2003US20030121065 Polyfunctional base sequence and artificial gene containing the same
06/26/2003US20030120071 Chemical compounds
06/26/2003US20030120069 1,1'-((Propane-1,3-diyl)dioxy)bis((11aS)-7-methoxy-2 -methy lidene-1,2,3,11-tetrahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazep in-5-one) derivatives; viricides, parasiticide, bactericides, gene therapy and treating cisplatin refractory disease
06/26/2003US20030120045 Immobilization onto polyoxyethylene glycol
06/26/2003US20030119881 Antivirals
06/26/2003US20030119869 1-(Piperidin-4-yl)benzimidazole or -triazole derivatives; agonists and antagonist for beta-chemokine (chemotactic cytokines) receptors; viricides; HIV; antiarthritic agents; atherosclerosis, psoriasis, antiallergens; multiple sclerosis
06/26/2003US20030119868 Gyrase inhibitors and uses thereof
06/26/2003US20030119859 Useful in the prophylaxis and treatment of respiratory diseases
06/26/2003US20030119857 Pyrimidinyl methyl indole derivatives with antibacterial activity
06/26/2003US20030119854 Compounds and methods for modulating CXCR3 function
06/26/2003US20030119848 A oxoquinolines or a 4-oxo-1,8-naphthyridines or 7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazine derivative for the treatment of tuberculosis, exhibits no cross resistance
06/26/2003US20030119838 Water-soluble phenylpyridazine compounds and compositions containing the same
06/26/2003US20030119835 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
06/26/2003US20030119823 5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydrox y-1,6-naphthyridine-7-carboxamide; preventing or treating hiv or aids
06/26/2003US20030119820 Substituted indoles
06/26/2003US20030119816 Cycline-dependent kinase protein inhibitors; antiproliferative agents
06/26/2003US20030119804 Otic microbial combination for treatment of animals with ruptured tympanic membrane
06/26/2003US20030119803 In particular N-epsilon-amino acid substituted L-lysine derivatives possessing aspartyl protease inhibitory properties.
06/26/2003US20030119793 CAK inhibitors and uses thereof
06/26/2003US20030119784 Treating and preventing diarrhea and scours
06/26/2003US20030119783 Aqueous compositions containing metronidazole
06/26/2003US20030119780 Therapeutical treatments
06/26/2003US20030119774 Compositions and methods for stimulating an immune response
06/26/2003US20030119760 Water insoluble polymer, such as ethyl cellulose; and an optimizing agent, such as a Eudragit acrylic polymer, optionally containing lactose, dicalcium phosphate and/or tricalcium phosphate
06/26/2003US20030119752 Inhibiting particularly the activity of hepatitis C virus NS3-NS4A protease; peptidomimetics having a bridged bicyclic moiety at the P2 position.
06/26/2003US20030119749 Novel compounds possessing antibacterial, antifungal or antitumor activity
06/26/2003US20030119748 Use for treatment of inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury.
06/26/2003US20030119724 Contain a hepatic ligand to direct an oligomer or "payload" to a hepatocyte intracellularly via a receptor-mediated, ligand-directed pathway; solid phase synthesis
06/26/2003US20030119722 Process for purifying glycopeptide phosphonate derivatives
06/26/2003US20030119715 Prevent retinoid binding; antiaging agents; activation cell differentiation
06/26/2003US20030119182 Immunotherapy; genetic engineering; anticancer agents
06/26/2003US20030119170 Porcine reproductive and respiratory syndrome vaccine, based on isolate JA-142
06/26/2003US20030119148 Amino-terminally truncated rantes as chemokine antagonists
06/26/2003US20030119111 G-protein coupled receptor, named 2871 receptor
06/26/2003US20030119101 Bactericides, fungicides; transporter proteins
06/26/2003US20030119095 Novel nucleic acid sequences encoding human vesicle transport protein-like and residue rat-like polypeptides
06/26/2003US20030119076 B7-like polynucleotides, polypeptides, and antibodies
06/26/2003US20030119013 Identification of essential genes of Aspergillus fumigatus and methods of use
06/26/2003US20030118678 Plant extracts as antiproliferative, viricides and antiparasitic agents
06/26/2003US20030118640 Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate
06/26/2003US20030118629 Water-in-oil emulsions with anionic groups, compositions, and methods
06/26/2003US20030118611 Epitopes confirmed to be recognized by T-cells derived from herpetic lesions or uterine cervix; vaccination
06/26/2003US20030118609 Administering a multimer of a human papillomavirus protein that is truncated at its amino terminus for immunization
06/26/2003US20030118608 Comprising Lelystad Agent in a live, attenuated, dead, or recombinant form
06/26/2003US20030118604 Comprising the 2-45 amino acid sequence of the N-terminal end of the core or nucleocapsid (p21) protein of the hepatitis C virus (HCV), excluding any protein or peptide compound comprising the N-terminal end
06/26/2003US20030118602 Peptides and immunologically functional variants thereof which are immunogenic epitopes recognized by CD8+ class I major histocompatibility complex restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus infection
06/26/2003US20030118591 Treatment of severe anthrax infection particularly inhalation pneumonia or gastrointestinal anthrax antigen by passive transfer to infected patients of plasma or derivatives, such as gammaglobulins or antibodies, against bacillus anthracis
06/26/2003US20030118588 Compound comprising an agonist anti-4-1BB antibody, or fragment thereof which stimulates the 4-1BB receptor; for treating tumors or infectious diseases
06/26/2003US20030118564 Intra-tumoral administration of il-12 encoding nucleic acid molecules
06/26/2003US20030118558 Lysin-deficient bacteriophages having reduced immunogenicity
06/26/2003US20030118528 Topical delivery of codrugs
06/26/2003US20030118507 Methods of using 46828, a human acyl-CoA synthetase
06/26/2003US20030117579 Medical devices having antimicrobial coatings thereon
06/26/2003CA2746308A1 Method for treating human papilloma virus
06/26/2003CA2471589A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003CA2471237A1 Adhesion inhibition of moulds
06/26/2003CA2471235A1 Inhibition of the asexual reproduction of fungi
06/26/2003CA2470723A1 3,4-dihydro-1h-isoquinolin-2-yl-derivatives
06/26/2003CA2470645A1 Streptococcus pneumoniae vaccine
06/26/2003CA2470629A1 Stabilized brivudine topical formulations
06/26/2003CA2470616A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/26/2003CA2470322A1 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
06/26/2003CA2470315A1 Methods of detecting modification of genetic material
06/26/2003CA2470236A1 Lactams as tachykinin antagonists
06/26/2003CA2470060A1 Improvements in pharmaceutical compositions
06/26/2003CA2469984A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
06/26/2003CA2469976A1 Improvements in pharmaceutical compositions
06/26/2003CA2469879A1 A novel sordarin derivative isolated from culture fermentations and functions as an antifungal agent
06/26/2003CA2469799A1 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
06/26/2003CA2469785A1 Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
06/26/2003CA2469205A1 Bioadhesive drug delivery system with enhanced gastric retention
06/26/2003CA2469048A1 Quinolinones as prostaglandin receptor ligands
06/26/2003CA2468986A1 Radioopaque sustained release pharmaceutical system
06/26/2003CA2468790A1 Chemokine mutants acting as chemokine antagonists
06/26/2003CA2468690A1 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
06/26/2003CA2468448A1 Benzodiazepine derivatives, preparation thereof and use thereof
06/26/2003CA2468413A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003CA2467279A1 Solubilized topoisomerase poison agents
06/26/2003CA2467271A1 Mycobacterial vaccine
06/26/2003CA2464512A1 Outer membrane vesicles from gram negative bacteria and use as a vaccine
06/26/2003CA2446292A1 Nucleic acid-associated proteins
06/25/2003EP1321476A2 Binding protein
06/25/2003EP1321463A1 Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections
06/25/2003EP1321147A1 Orally administrable solid ribavirin dosage forms and process for making them
06/25/2003EP1320621A2 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
06/25/2003EP1320614A2 Novel proteases
06/25/2003EP1320600A1 Transporters and ion channels
06/25/2003EP1320599A2 Pd-l2 molecules: pd-1 ligands and uses therefor
06/25/2003EP1320584A2 Transferases
06/25/2003EP1320581A1 T cell receptor transfer into a candidate effector cell or a precursor thereof
06/25/2003EP1320550A2 G-protein coupled receptors
06/25/2003EP1320548A2 Transporters and ion channels
06/25/2003EP1320547A1 Transfer factor from birds eggs
06/25/2003EP1320540A2 Peptidomimetic protease inhibitors
06/25/2003EP1320533A1 Prodrugs of a 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotic
06/25/2003EP1320531A2 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/25/2003EP1320530A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
06/25/2003EP1320529A1 Quinoline derivatives as antibacterials
06/25/2003EP1320525A1 Antibacterial mutilins
06/25/2003EP1320384A1 The synergetic effects of hgf and antibacterial treatment